Cargando…

A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation

A total of 20% to 50% of prostate cancer (PCa) patients leave the surgery room with positive tumour margins. The intraoperative combination of fluorescence guided surgery (FGS) and photodynamic therapy (PDT) may be very helpful for improving tumour margin delineation and cancer therapy. PSMA is a tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Capozza, Martina, Stefania, Rachele, Dinatale, Valentina, Bitonto, Valeria, Conti, Laura, Grange, Cristina, Skovronova, Renata, Terreno, Enzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657290/
https://www.ncbi.nlm.nih.gov/pubmed/36361667
http://dx.doi.org/10.3390/ijms232112878
_version_ 1784829656060395520
author Capozza, Martina
Stefania, Rachele
Dinatale, Valentina
Bitonto, Valeria
Conti, Laura
Grange, Cristina
Skovronova, Renata
Terreno, Enzo
author_facet Capozza, Martina
Stefania, Rachele
Dinatale, Valentina
Bitonto, Valeria
Conti, Laura
Grange, Cristina
Skovronova, Renata
Terreno, Enzo
author_sort Capozza, Martina
collection PubMed
description A total of 20% to 50% of prostate cancer (PCa) patients leave the surgery room with positive tumour margins. The intraoperative combination of fluorescence guided surgery (FGS) and photodynamic therapy (PDT) may be very helpful for improving tumour margin delineation and cancer therapy. PSMA is a transmembrane protein overexpressed in 90–100% of PCa cells. The goal of this work is the development of a PSMA-targeted Near InfraRed Fluorescent probe to offer the surgeon a valuable intraoperative tool for allowing a complete tumour removal, implemented with the possibility of using PDT to kill the eventual not resected cancer cells. PSMA-617 binding motif was conjugated to IRDye700DX-NHS and the conjugation did not affect the photophysical characteristics of the fluorophore. The affinity of IRDye700DX-PSMA-617 towards PCa cells followed the order of their PSMA expression, i.e., PC3-PIP > LNCaP > PC3, PC3-FLU. NIRF imaging showed a significant PC3-PIP tumour uptake after the injection of 1 or 5 nmol with a maximum tumour-to-muscle ratio (ca. 60) observed for both doses 24 h post-injection. Importantly, urine, healthy prostate, and the bladder were not fluorescent at 24 h post-injection. Flow cytometry and confocal images highlighted a co-localization of PSMA+ cells with IRDye700DX-PSMA uptake. Very interestingly, ex vivo analysis on a tumour specimen highlighted a significant PSMA expression by tumour-associated macrophages, likely attributable to extracellular vesicles secreted by the PSMA(+) tumour cells. FGS proved that IRDye700DX-PSMA was able to easily delineate tumour margins. PDT experiments showed a concentration-dependent decrease in cell viability (from 75% at 10 nM to 12% at 500 nM), whereas controls did not show any cytotoxicity. PC3-PIP tumour-bearing mice subjected to photodynamic therapy showed a delayed tumour growth. In conclusion, a novel PSMA-targeted NIRF dye with dual imaging-PDT capabilities was synthesized and displayed superior specificity compared to other small PSMA targeted molecules.
format Online
Article
Text
id pubmed-9657290
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96572902022-11-15 A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Capozza, Martina Stefania, Rachele Dinatale, Valentina Bitonto, Valeria Conti, Laura Grange, Cristina Skovronova, Renata Terreno, Enzo Int J Mol Sci Article A total of 20% to 50% of prostate cancer (PCa) patients leave the surgery room with positive tumour margins. The intraoperative combination of fluorescence guided surgery (FGS) and photodynamic therapy (PDT) may be very helpful for improving tumour margin delineation and cancer therapy. PSMA is a transmembrane protein overexpressed in 90–100% of PCa cells. The goal of this work is the development of a PSMA-targeted Near InfraRed Fluorescent probe to offer the surgeon a valuable intraoperative tool for allowing a complete tumour removal, implemented with the possibility of using PDT to kill the eventual not resected cancer cells. PSMA-617 binding motif was conjugated to IRDye700DX-NHS and the conjugation did not affect the photophysical characteristics of the fluorophore. The affinity of IRDye700DX-PSMA-617 towards PCa cells followed the order of their PSMA expression, i.e., PC3-PIP > LNCaP > PC3, PC3-FLU. NIRF imaging showed a significant PC3-PIP tumour uptake after the injection of 1 or 5 nmol with a maximum tumour-to-muscle ratio (ca. 60) observed for both doses 24 h post-injection. Importantly, urine, healthy prostate, and the bladder were not fluorescent at 24 h post-injection. Flow cytometry and confocal images highlighted a co-localization of PSMA+ cells with IRDye700DX-PSMA uptake. Very interestingly, ex vivo analysis on a tumour specimen highlighted a significant PSMA expression by tumour-associated macrophages, likely attributable to extracellular vesicles secreted by the PSMA(+) tumour cells. FGS proved that IRDye700DX-PSMA was able to easily delineate tumour margins. PDT experiments showed a concentration-dependent decrease in cell viability (from 75% at 10 nM to 12% at 500 nM), whereas controls did not show any cytotoxicity. PC3-PIP tumour-bearing mice subjected to photodynamic therapy showed a delayed tumour growth. In conclusion, a novel PSMA-targeted NIRF dye with dual imaging-PDT capabilities was synthesized and displayed superior specificity compared to other small PSMA targeted molecules. MDPI 2022-10-25 /pmc/articles/PMC9657290/ /pubmed/36361667 http://dx.doi.org/10.3390/ijms232112878 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Capozza, Martina
Stefania, Rachele
Dinatale, Valentina
Bitonto, Valeria
Conti, Laura
Grange, Cristina
Skovronova, Renata
Terreno, Enzo
A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation
title A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation
title_full A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation
title_fullStr A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation
title_full_unstemmed A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation
title_short A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation
title_sort novel psma-targeted probe for nirf-guided surgery and photodynamic therapy: synthesis and preclinical validation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657290/
https://www.ncbi.nlm.nih.gov/pubmed/36361667
http://dx.doi.org/10.3390/ijms232112878
work_keys_str_mv AT capozzamartina anovelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT stefaniarachele anovelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT dinatalevalentina anovelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT bitontovaleria anovelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT contilaura anovelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT grangecristina anovelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT skovronovarenata anovelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT terrenoenzo anovelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT capozzamartina novelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT stefaniarachele novelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT dinatalevalentina novelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT bitontovaleria novelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT contilaura novelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT grangecristina novelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT skovronovarenata novelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation
AT terrenoenzo novelpsmatargetedprobefornirfguidedsurgeryandphotodynamictherapysynthesisandpreclinicalvalidation